PROMs at the American Society of Clinical Oncology conference, May 2018

PROMs at the American Society of Clinical Oncology conference, May 2018

The benefits of incorporating digital patient-reported outcomes measurement into cancer treatment featured prominently again at this year’s American Society of Clinical Oncology (ASCO) conference. 

The beneficial results from last year’s publication in JAMA by Basch et al. were recapped, specifically that in the study group using digital PROMs alongside usual treatments:

  • 31% reported quality of life benefits at 6 months

  • there were 7% fewer Emergency Room visits

  • mean overall survival was 5 months longer (translating to an absolute 5 year survival benefit of 8%)

There was also a discussion about barriers to adoption of PROs in routine practice that centred on the need for cost-effective, specialist digital tools.

Read more about the discussion at the conference here.

MCO finalists in HealthInvestor Awards 2018, February 2018


MCO have once again been named as finalists in the HealthInvestor 2018 awards ‘Health Technology Company of the Year’ category. The awards aim to recognise innovation in the independent healthcare sector and the judges look for those who have made an outstanding contribution to healthcare in 2017. The results will be announced at Grosvenor House Hotel on 13th June.

Click here to read more.

MCO Awarded Phase 2 Funding in NHS Scotland “Cancer Innovation Challenge”, February 2018

MCO are delighted to announce that we have been awarded second phase funding from the Cancer Innovation Challenge (CIC). The CIC is “a project funded by the Scottish Funding Council (SFC) to encourage Innovation Centres in Scotland to work in partnership to help Scotland become a world leading carer for people with cancer.”

To read the CIC Phase 2 press release please click here.

MCO have already started configuring the system, based on requirements and designs developed in phase 1, and are about to start collecting patient reported outcomes data for patients with haematological cancer at NHS Ayrshire and Arran. MCO will incorporate guidance from Macmillan Cancer Support  and make the system interoperable with Orion Healthcare, an established clinical portal in Scotland.

The news featured in the national newspaper of Scotland, the Scotsman. Click here to read the article.